Antenatal Care, Physiological Changes in Pregnancy & Fetal Assessment

Maternal and obstetric nursing encompasses the clinical assessment, health promotion, disease prevention, and acute management of women throughout the antepartum, intrapartum, and postpartum continuum. Providing competent care requires an intimate mastery of maternal physiological adaptations, accurate pregnancy dating and clinical diagnosis, structured antenatal care (ANC) interventions, and rigorous antepartum fetal surveillance.

---

1. Maternal Physiological Adaptations to Pregnancy

Pregnancy induces profound biochemical, mechanical, and endocrinological adaptations across every maternal organ system. These adaptations are designed to accommodate fetal development, prepare the maternal body for labor and lactation, and protect against intrapartum hemorrhage.

Cardiovascular System

• Intravascular Volume Expansion: Total blood volume increases by 40% to 50% (approximately 1,200 to 1,500 mL) above non-pregnant baselines. Plasma volume expands earlier and more substantially (approx. 50%) than total red blood cell volume (approx. 20% to 30% with iron supplementation). This disproportionate hemodilution results in physiologic anemia of pregnancy. According to World Health Organization (WHO) and Government of India criteria, anemia in pregnancy is defined as a hemoglobin ($Hb$) concentration $< 11.0\text{ g/dL}$ (or hematocrit $< 33\%$) in the first and third trimesters, and $< 10.5\text{ g/dL}$ in the second trimester.
• Cardiac Output & Heart Rate: Resting cardiac output rises by 30% to 50% (peaking between 28 and 32 weeks of gestation), mediated primarily by an increased stroke volume early in gestation and sustained by an elevated resting maternal heart rate (which increases by 10 to 15 beats/min by the third trimester).
• Vascular Resistance & Blood Pressure: Systemic vascular resistance (SVR) decreases markedly due to progesterone-mediated smooth muscle relaxation and the low-resistance uteroplacental vascular shunt. Consequently, arterial blood pressure drops during the second trimester (systolic dropping 5–10 mmHg, diastolic dropping 10–15 mmHg) before returning to pre-pregnancy baselines by term.
• Supine Hypotensive Syndrome (Aortocaval Compression): When a pregnant woman assumes the supine position during the second half of gestation, the enlarged gravid uterus compresses the inferior vena cava (IVC) against the vertebral column. This markedly obstructs venous return to the right atrium, precipitating a sudden drop in cardiac preload, stroke volume, and arterial blood pressure. The patient develops pallor, dizziness, diaphoresis, lightheadedness, nausea, and reflex bradycardia or tachycardia, while placental hypoperfusion compromises fetal oxygenation. Immediate Management: Reposition the patient into the left lateral decubitus position, which displaces the uterus off the IVC and instantly restores venous return.

Respiratory System

• Anatomical Adjustments: The expanding uterus elevates the diaphragm by approximately 4 cm, while thoracic cage diameter expands transversely by 2 cm and the subcostal angle widens from 68° to roughly 103°.
• Ventilatory Mechanics: Progesterone acts directly on the medullary respiratory center to increase sensitivity to carbon dioxide. This elevates tidal volume ($V_T$) by 30% to 40% without significantly changing respiratory rate. Minute ventilation increases by nearly 50%.
• Functional Residual Capacity (FRC): FRC and residual volume decrease by roughly 20% due to diaphragmatic elevation. Oxygen consumption increases by 20% to 30% to meet fetal-placental metabolic demands.
• Compensated Respiratory Alkalosis: Maternal hyperventilation lowers arterial carbon dioxide tension ($PaCO_2$) to 27–32 mmHg (non-pregnant baseline: 35–45 mmHg), producing a mild, compensated respiratory alkalosis ($pH\text{ 7.40–7.45}$, plasma bicarbonate $18–22\text{ mEq/L}$). This established concentration gradient facilitates the passive diffusion of carbon dioxide from fetal circulation across the placenta into maternal blood.

Renal and Urinary System

• Renal Hemodynamics: Renal plasma flow (RPF) and Glomerular Filtration Rate (GFR) increase by approximately 50% starting in the first trimester. As a direct result, serum creatinine and blood urea nitrogen (BUN) levels decline significantly. Normal maternal serum creatinine falls to 0.4–0.6 mg/dL (levels $\ge 0.9\text{ mg/dL}$ suggest underlying renal pathology).
• Physiological Glucosuria: The sharp rise in GFR can overwhelm the tubular transport maximum for glucose ($Tm_G$), resulting in intermittent, physiological glucosuria in up to 50% of pregnant women without maternal hyperglycemia; however, gestational diabetes mellitus must always be ruled out.
• Hydronephrosis & Urinary Stasis: Elevated progesterone induces ureteral smooth muscle dilation and hypomotility. Furthermore, dextrorotation of the gravid uterus, combined with compression by dilated right ovarian venous complexes, produces physiological dilation of the renal pelves and ureters (predominantly the right ureter). This urinary stasis predisposes pregnant women to asymptomatic bacteriuria, acute cystitis, and pyelonephritis.

Endocrine System

• Human Chorionic Gonadotropin (hCG): Synthesized by syncytiotrophoblastic cells, hCG prevents the degeneration of the corpus luteum, preserving its secretion of progesterone and estrogen during the first 8 to 10 weeks of pregnancy until the placenta assumes endocrine autonomy (the luteal-placental shift). Serum hCG doubles roughly every 48 to 72 hours, peaking at 8 to 10 weeks of gestation (around 100,000 mIU/mL) before declining to a stable plateau.
• Human Placental Lactogen (hPL / Human Chorionic Somatomammotropin): Secreted by the placenta in increasing quantities as placental mass grows. Acts as a potent insulin antagonist, decreasing maternal insulin sensitivity to spare glucose, amino acids, and free fatty acids for transplacental transport to the fetus. This anti-insulin action underlies the diabetogenic state of late pregnancy.
• Progesterone: Termed the "hormone of pregnancy," progesterone maintains the secretory endometrium, suppresses myometrial smooth muscle contractility (preventing preterm contractions), relaxes vascular smooth muscle, and induces lower esophageal sphincter relaxation (causing pyrosis/heartburn) and gastrointestinal hypomotility (causing constipation).
• Estrogen (predominantly Estriol, E3): Promotes uterine myometrial hypertrophy, augments uteroplacental blood flow, stimulates ductal development in the breasts, and enhances hepatic synthesis of coagulation factors (Factors VII, VIII, IX, X, and fibrinogen), producing a marked hypercoagulable state that protects against delivery-associated hemorrhage but elevates venous thromboembolism risk.

Integumentary System

• Chloasma (Melasma Gravidarum): Irregular, blotchy, hyperpigmented patches appearing symmetrically over the forehead, cheeks, and nose (the "mask of pregnancy"), stimulated by elevated melanocyte-stimulating hormone (MSH) and estrogen; typically fades postpartum.
• Linea Nigra: A dark, pigmented vertical line extending along the midline of the anterior abdomen from the symphysis pubis to the xiphoid process, resulting from hyperpigmentation of the linea alba.
• Striae Gravidarum: Linear, reddish-purple atrophic bands ("stretch marks") developing on the abdomen, breasts, and thighs due to mechanical cutaneous stretching and adrenocortical hormonal breakdown of dermal collagen fibers.
• Vascular Spiders & Palmar Erythema: Elevated circulating estrogen levels promote peripheral capillary dilation, manifesting as angiomas (spider nevi) on the neck, thorax, and face, alongside bilateral erythematous mottling of the palms.

---

2. Diagnosis and Signs of Pregnancy

Clinical signs of pregnancy are systematically classified into three distinct categories based on their diagnostic certainty: presumptive, probable, and positive.

Clinical Pearl: Fetal heart sounds must be clearly distinguished from maternal pelvic vascular bruits: the uterine souffle is a soft, blowing murmur synchronous with the maternal arterial pulse, caused by blood rushing through dilated uterine arteries; the funic (umbilical) souffle is a sharp, whistling sound synchronous with the fetal heart rate, generated by blood coursing through the umbilical arteries.

---

3. Antenatal Care Protocols

Antenatal care (ANC) encompasses systematic health supervision, screening, prophylaxis, and maternal education throughout gestation to achieve optimal maternal and neonatal outcomes.

ANC Visit Schedules

• WHO / Ministry of Health and Family Welfare (MoHFW) India Minimum Schedule: Under National Health Mission (NHM) guidelines, every pregnant woman must receive a minimum of 4 focused antenatal visits:
  1. First Visit: Within the first trimester (before 12 weeks of gestation) for early pregnancy registration, comprehensive baseline screening, and dating.
  2. Second Visit: Between 14 and 26 weeks of gestation (around 20 weeks) to assess fetal growth and maternal well-being.
  3. Third Visit: Between 28 and 34 weeks of gestation (around 32 weeks) to screen for gestational hypertension, preeclampsia, intrauterine growth restriction, and twin gestation.
  4. Fourth Visit: At 36 weeks to term to determine fetal presentation, position, lie, pelvic adequacy, and birth preparedness.
  • Note: WHO's 2016 antenatal care model recommends at least eight contacts; Indian programme questions test the minimum of four visits.
• Ideal Clinical ANC Schedule (Standard Practice):
  • Every 4 weeks (monthly) until 28 weeks of gestation.
  • Every 2 weeks (biweekly) from 28 to 36 weeks of gestation.
  • Every week from 36 weeks until delivery.

Calculation of Expected Date of Delivery (Naegele's Rule)

Naegele's rule provides a standardized mathematical formula for calculating the Expected Date of Delivery ($EDD$) based on the first day of the normal Last Menstrual Period ($LMP$), assuming a regular 28-day menstrual cycle:

$\text{EDD} = \text{First Day of LMP} + 9\text{ Calendar Months} + 7\text{ Days}$ $\text{Alternatively: } \text{EDD} = \text{First Day of LMP} - 3\text{ Calendar Months} + 7\text{ Days} + 1\text{ Year}$

• Worked Example 1: If the first day of LMP is June 10, 2026:
  • Add 7 days: June $10 + 7 = \text{June 17}$.
  • Subtract 3 months (or add 9 months): June minus 3 months = March.
  • Advance 1 year: March 17, 2027.
• Worked Example 2: If the first day of LMP is January 20, 2026:
  • Add 7 days: January $20 + 7 = \text{January 27}$.
  • Add 9 months: January plus 9 months = October.
  • Same calendar year: October 27, 2026.

Maternal Immunization: Tetanus & Adult Diphtheria (Td)

Under the Universal Immunization Programme (UIP) in India, Tetanus and adult Diphtheria (Td) vaccine has completely replaced Tetanus Toxoid (TT) to prevent maternal and neonatal tetanus as well as protect against diphtheria:

• Dose 1 (Td-1): Administered as early in pregnancy as possible (ideally during the first ANC visit in the first trimester).
• Dose 2 (Td-2): Administered 4 weeks after Td-1 (must be completed at least 4 weeks prior to the anticipated delivery date).
• Td Booster Dose: A single booster dose is administered if the woman received two complete doses of TT/Td during a pregnancy occurring within the preceding 3 years.

Antenatal Nutritional Supplementation

• Iron and Folic Acid (IFA) Prophylaxis: In accordance with the Anemia Mukt Bharat guidelines, all pregnant women must receive one red IFA tablet containing 60 mg of elemental iron and 500 mcg (0.5 mg) of folic acid daily for a minimum of 180 days, initiated in the second trimester (from the 14th to 16th week of gestation onward) and continued for 180 days postpartum during lactation. Women diagnosed with anemia ($Hb < 11\text{ g/dL}$) receive therapeutic doses (two IFA tablets daily under Anemia Mukt Bharat) with repeat hemoglobin checks; severe anemia is referred.
• Pre-conceptional Folic Acid: To prevent neural tube defects (NTDs) such as anencephaly and spina bifida, all women planning pregnancy must consume 400 mcg (0.4 mg) of folic acid daily starting at least 1 month prior to conception and continued throughout the first trimester (up to 12 weeks). Women with a prior history of an infant with an NTD, pregestational diabetes, or receiving enzyme-inducing anticonvulsants must receive a high-risk prophylactic dose of 5 mg daily.
• Calcium Supplementation: Pregnant women are prescribed 1,000 mg of elemental calcium daily (two tablets of 500 mg each) from the 14th week of gestation through 6 months postpartum to support fetal skeletal mineralization and decrease the incidence of gestational hypertensive disorders. Crucial Rule: Calcium and iron tablets must never be ingested concurrently, as calcium competitively inhibits non-heme iron absorption; patients are instructed to take calcium with meals and iron 2 hours apart or with vitamin C-rich fluids.

---

4. Fetal Assessment and Electronic Fetal Monitoring (EFM)

Antepartum and intrapartum fetal assessment detects uteroplacental compromise and fetal hypoxia early, enabling timely clinical interventions before irreversible neurological injury or intrauterine fetal demise occurs.

Non-Stress Test (NST)

The NST evaluates the acceleration of fetal heart rate in response to spontaneous fetal body movements, reflecting an intact, oxygenated fetal autonomic nervous system:

• Reactive (Reassuring) NST: Defined by the occurrence of $\ge 2$ fetal heart rate accelerations within a 20-minute monitoring window. An acceleration is defined as a peak elevation of $\ge 15\text{ beats/min}$ above baseline lasting $\ge 15\text{ seconds}$ from onset to return (the "15-by-15" rule). In gestations $< 32$ weeks, an acceleration is defined as $\ge 10\text{ beats/min}$ lasting $\ge 10\text{ seconds}$.
• Non-Reactive (Non-Reassuring) NST: Defined by the absence of qualifying accelerations over a 40-minute testing period (extended to account for normal fetal sleep cycles, which typically last 20 to 40 minutes). If non-reactive, the nurse provides vibroacoustic stimulation (VAS), provides maternal oral fluids/glucose, reposition the patient, and schedules a comprehensive Biophysical Profile or Contraction Stress Test.

Biophysical Profile (BPP / Manning Score)

The BPP couples real-time ultrasound imaging with the NST over a continuous 30-minute observation window, scoring 5 discrete biophysical variables:

1. Fetal Breathing Movements (FBM): At least 1 continuous episode of rhythmic fetal breathing movements lasting $\ge 30\text{ seconds}$ (Score: 2; absent or $< 30\text{ s} = 0$).
2. Gross Fetal Body Movements: At least 3 discrete body or limb movements in 30 minutes (Score: 2; $< 3\text{ movements} = 0$).
3. Fetal Tone: At least 1 active extension episode of an extremity or spine with immediate return to flexion, or opening and closing of a hand (Score: 2; slow extension or partial flexion = 0).
4. Fetal Heart Rate Reactivity (NST): Reactive NST satisfying the 15-by-15 criteria (Score: 2; non-reactive = 0).
5. Amniotic Fluid Volume (AFV): At least 1 single deepest vertical pocket of amniotic fluid measuring $\ge 2\text{ cm}$ in two perpendicular planes without containing umbilical cord loops (or an Amniotic Fluid Index [AFI] between 5.0 and 25.0 cm; Score: 2; single pocket $< 2\text{ cm}$ or $\text{AFI} < 5\text{ cm} = 0$).

• Interpretation:
  • 8/10 or 10/10: Normal, reassuring; fetal hypoxia is exceedingly remote ($< 1$ per 1,000 within 1 week).
  • 6/10: Equivocal; suspected chronic asphyxia. If gestational age is $\ge 37$ weeks or if oligohydramnios is present, delivery is indicated; if preterm and fluid is normal, repeat BPP within 12 to 24 hours.
  • 0/10 to 4/10: Strongly abnormal; severe chronic fetal compromise and high risk of perinatal death; mandates immediate hospital admission and urgent delivery.

Contraction Stress Test (CST / Oxytocin Challenge Test)

The CST assesses uteroplacental respiratory reserve by observing the fetal heart rate response to transient, uterine contraction-induced reductions in placental blood flow:

• Testing Criteria: Requires a minimum of 3 uterine contractions lasting at least 40 seconds each within a 10-minute window, induced via nipple stimulation or dilute intravenous oxytocin infusion.
• Negative CST (Reassuring / Normal): Characterized by no late or significant variable decelerations throughout the test. Indicates adequate placental reserve.
• Positive CST (Non-Reassuring / Abnormal): Characterized by persistent and consistent late decelerations occurring with $\ge 50\%$ of contractions, even if contraction frequency is fewer than 3 in 10 minutes. Demonstrates uteroplacental insufficiency and fetal vulnerability to intrapartum hypoxia; typically mandates cesarean delivery.

Electronic Fetal Monitoring (EFM) Decelerations: The VEAL CHOP Framework

Intrapartum cardiotocography continuously monitors baseline FHR, baseline variability, accelerations, and periodic decelerations:

• Baseline FHR: Normal range is 110 to 160 beats/min. Baseline bradycardia is $< 110\text{ bpm}$ lasting $\ge 10\text{ minutes}$; tachycardia is $> 160\text{ bpm}$ lasting $\ge 10\text{ minutes}$ (frequently caused by maternal pyrexia, chorioamnionitis, fetal hypoxemia, or terbutaline).
• Baseline Variability: Fluctuations in baseline FHR irregular in amplitude and frequency: absent (amplitude undetectable), minimal ($> 0\text{ and } \le 5\text{ bpm}$), moderate (6 to 25 bpm, the hallmark of normal fetal acid-base balance), or marked ($> 25\text{ bpm}$).

Step-by-Step Intrauterine Resuscitation Protocol

When late decelerations, severe prolonged decelerations, or recurrent variable decelerations appear, the nurse must immediately execute the standardized resuscitation sequence:

1. Reposition the Patient: Immediately place the mother in the left lateral decubitus position (or alternate to right lateral / knee-chest) to relieve aortocaval compression and maximize uterine blood flow.
2. Discontinue Uterotonic Agents: Immediately stop any running oxytocin (Pitocin) infusion or remove dinoprostone vaginal inserts to arrest uterine hyperstimulation and allow placental reperfusion.
3. Administer Oxygen: Deliver high-flow oxygen at 8 to 10 L/min via a tight-fitting non-rebreather face mask to elevate maternal arterial oxygen tension and increase oxygen delivery to the placental bed.
4. Hydrate with IV Crystalloids: Administer a rapid intravenous bolus of 500 to 1,000 mL of lactated Ringer's or normal saline to expand maternal intravascular volume and enhance placental perfusion.
5. Perform Vaginal Examination: Check for rapid cervical dilation, fetal head descent, or an occult/overt umbilical cord prolapse.
6. Correct Maternal Hypotension: If hypotension is present (e.g., following epidural analgesia), administer IV ephedrine or phenylephrine as ordered.
7. Notify Provider & Prepare for Delivery: Immediately summon the obstetric provider; if the FHR pattern remains refractory to resuscitation, prepare the patient and operating room for emergent operative or cesarean delivery.